We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within
19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G …

The clinical features and immune responses of asymptomatic individuals infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been well described. …

Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed
vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus,
causes severe pneumonia and has spread throughout the globe rapidly. The …

Background We aim to investigate the profile of acute antibody response in COVID-19 patients,
and provide proposals for the usage of antibody test in clinical practice. Methods A multi-…

In December 2019, the corona virus disease 2019 (COVID-19) caused by novel coronavirus
(SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide. Few information …

Background & Aims Current antiviral therapies help keep HBV under control, but they are
not curative, as they are unable to eliminate the intracellular viral replication intermediate …

The appropriate regulation of photocatalyst band structure by simultaneous introduction of
active sites is an effective strategy in constructing efficient photocatalytic systems for biomass …

Nitriles are versatile nitrogen-containing scaffolds that exist widely in medicines, dyes and
functional materials, and are typically synthesized over homogeneous catalysts under …

Chemocatalytic conversion of biomass-based saccharides to lactic acid (LA) is one of the
prospective routes for biomass valorization, but generally suffers from harsh reaction …